In patients with metastatic disease, several options are now available (namely ipilimumab, nivolumab, pembrolizumab, cytotoxics, interleukin-2, anti-MEK, and anti-BRAF agents in BRAF mutated MM), and so long-term survivors are a realistic possibility. The gene discussed is IL2; the disease is Miyoshi myopathy.